Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Bilcare, CSIR in Authentication Technology Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Bilcare, CSIR in Authentication Technology Pact

Will advance nonClonableID technology

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Council of Scientific and Industrial Research (CSIR), under its New Millennium Indian Technology Leadership Initiative (NMITLI), has approved the implementation of customized adaptation of nonClonableID technology to establish authenticity of medical products. Dr. Praful Naik, executive director and chief scientific officer of Bilcare Ltd., has been designated principal investigator for the project.
 
The CSIR-NMITLI-Bilcare team will work to demonstrate the ability of a new nonClonableID technology to address the unmet needs in medical product authentication and patient safety. The nonClonableID technology is based on novel aspects of material science and uses the law of randomness to create unique non-duplicable fingerprints. These fingerprints when processed, digitized and activated can function as unique identification tags. The key objectives of the CSIR-NMITLI project is to demonstrate the utility of the nonClonableID tags in establishing product accountability through secured traceability from the point of origin to the point of dispensation, authenticity check and establishing e-pedigree.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics